Antidepressant with novel mechanism of action shows promise in Phase 2 trial

Abstract

Daily oral administration of SAGE‐217, a synthetic neurosteroid and positive allosteric GABAA receptor modulator, reduced depressive symptoms relative to placebo in a Phase 2 study involving 89 patients with major depression. The promising results were seen both among patients taking and not taking an antidepressant, researchers reported. Study results were published Sept. 5 in the New England Journal of Medicine.